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ABSTRACT
Objective: A stability indicating reverse-phase high-performance liquid chromatography (RP-HPLC) method was developed and validated for the 
estimation of emtricitabine (EMT), rilpivirine (RIL), and tenofovir alafenamide (TAF) in combined dosage forms and its API.
Methods: Chromatographic separation was achieved on Waters ACQUITY RP-HPLC with PDA detector having Zodiac C18 Column (250×4.6×5µ) using 
mobile phase mixture of phosphate buffer: acetonitrile in the ratio of 40:60 v/v at 262 nm.
Results: The assay was performed with tablets, and the % assay was found to be 100.104 for EMT, 99.74 for RIL, and 102.41 for TAF which shows that 
the method is useful for routine analysis. The linearity was found to be linear with a correlation coefficient of 0.999, which shows that the method 
is capable of producing good sensitivity. The retention time (RT) of EMT, RIL, and TAF using optimum conditions was found to be 2.517, 3.273, and 
6.697 min. Forced degradation studies (FDS) were performed on sample using acid, base, thermal, photolytic, and peroxide degradation.
Conclusion: Due to its simplicity, rapidness, high precision, and low RT value, this method was successfully applied to the estimation of EMT, RIL, and 
TAF combined dosage form. The drugs were found to be stable at FDS, and the net degradation was found to be within the limits.
Keywords: Rilpivirine, Emtricitabine, Tenofovir alafenamide, Reverse-phase high-performance liquid chromatography.
INTRODUCTION
Emtricitabine (EMT) [1-3] is a nucleoside reverse transcriptase 
inhibitor (NRTI) for the treatment of HIV infection in adults which works 
by inhibiting reverse transcriptase, the enzyme that copies HIV RNA 
into new viral DNA, resulting in early chain termination. Its chemical 
name is 5-fluoro-1-[(2R, 5S)-2-(hydroxymethyl)-1, 3-oxathiolan-5-yl] 
cytosine and the molecular formula is C8H10FN3O3S.
Tenofovir alafenamide (TAF) [4-8] is a NRTI and a novel ester prodrug 
of the antiretroviral tenofovir. Its chemical name is ({[(2R)-1-(6-amino-
9H-purin-9-yl)propan-2-yl]oxy}methyl) phosphoric acid and the 
molecular formula is C21H29N6O5P.
Rilpivirine (RIL) [9] is non-NRTI (NNRTI) which is used for the 
treatment of HIV-1 infections in treatment-naive patients. RIL is a non-
competitive NNRTI that binds to reverse transcriptase. Its chemical name 
is 4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)
pyrimidin-2-yl]amino}benzonitrile and the molecular formula is C22H18N6.
According to literature survey, there was no official method for the 
simultaneous estimation of EMT, RIL, and TAF, but only few reverse-
phase high-performance liquid chromatography (RP-HPLC) [10-12] 
methods have been described in the literature for individual or in 
combination with other drugs for the estimation which were found to 
have high retention time (RT) and more total run time for analysis. There 
was no stability indicating analytical methods reported for simultaneous 
estimation of EMT, RIL, and TAF. The aim of the present work deals with 
the development of RP-HPLC method along with forced stability studies 
which was found to be simple, precise, accurate, and shorter RT which 
makes this method good for routine analysis in research institutions 
which justify that the developed method is advantageous over the 
existing method as per the ICH as shown in Fig. 1.
METHODS
Chemical and reagents
Pure samples were obtained from Hetero Pharma Ltd., Hyderabad, 
India; marketed formulation of combination was purchased from 
local market; tetrahydrofuran and acetonitrile (ACN) were obtained 
from Rankem, India Co. Ltd., methanol, water, and ammonium acetate 
were obtained from LiChrosolv (Merck), and potassium dihydrogen 
orthophosphate (ODP) was obtained from Molychem.
Buffer and mobile phase (MP) preparation
17 g of ammonium acetate was taken in a volumetric flask and add 
90 ml of water in it and mix well and make up the volume to 100 ml 
with water which was used as buffer.
The mixture of 40 volumes of 0.1N ODP buffer and 60 volumes of ACN 
(40:60 v/v) was prepared and sonicated for 10 min which was used as MP.
Standard and sample preparation
Weigh accurately 13 mg of EMT, 1.62 mg of RIL, and 20 mg of TAF in 
100 ml of volumetric flask and dissolve in 10 ml of MP and make up the 
volume with MP. From that, 13 µg/ml of EMT, 1.62 µg/ml of RIL, and 
20 µg/ml of TAF was prepared by diluting 5.3 ml–10 ml with MP which 
was used as stock solution.
5 tablets were weighed and taken into a mortar and crushed to 
fine powder and uniformly mixed. Weight equivalent to 34.62 mg 
and dissolved. Further dilutions were prepared in five replicates of 
13 μg/ml of EMT, 1.62 μg/ml of RIL, and 20 µg/ml of TAF which were 
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made by adding 5.3 ml of stock solution to 10 ml of MP which was used 
as sample solution.
Instrumentation
The separation was carried out on Waters Acquity RP-HPLC with 
PDA detector having Empower 2 software with Zodiac C18 Column 
(250×4.6×5 µ), Nicolet Evolution 100 UV/visible, METSAR pH meter, 
POWERSONIC 405 sonicator, Afcoset er-200a analytical balance and 
pipettes, beakers, and burettes made of borosil were used.
Method validation [13-15]
The analytical method was validated with respect to parameters such 
as linearity, limit of quantification (LOQ), limit of detection (LOD), 
precision, accuracy, selectivity, recovery, and ruggedness.
Forced stability studies
Preparation of solution
Weight equivalent to 1 tablet, i.e., 200 mg of EMT, 25 mg of RIL, and 
25 mg of TAF into 50 ml capacity standard volumetric flask. The 
contents in the flask were dissolved using methanol and sonicate it and 
diluted up to the mark with methanol.
Acid degradation condition
Accurately 5.0 ml aliquot of above stock solution was transferred into a 
50 ml round bottom flask, and 2.5 ml of 0.1N HCl was added. The flask 
was refluxed at 60°C for 30 min using evaporator and then allowed to 
cool. Then neutralize with 0.1N NaOH solution. Using MP, finally volume 
was made up to the mark and percentage of degradation was calculated.
Alkali degradation condition
Accurately 5.0 ml aliquot of above stock solution was transferred into a 
50 ml round bottom flask, and 2.5 ml of 0.1N NaOH was added. The flask 
was refluxed at 60°C for 30 min using evaporator and then allowed to 
cool. Then neutralize with 0.1N HCl solution. Finally, volume was made 
up to the mark with MP, and percentage of degradation was calculated.
Thermal induced degradation condition
200 mg of EMT, 25 mg of RIL, and 300 mg of TAF were weighed 
accurately and transfer into four different Petri dishes and kept in a hot 
air oven for 8 h at 105°C. The content in the flasks was dissolved using 
methanol and diluted up to the mark with methanol, and the percentage 
of degradation was calculated.
Photolytic degradation condition
A 5 ml aliquot of above stock solution was exposed to sunlight for about 
6 h and then the sample diluted with 5 ml of MP, and percentage of 
degradation was calculated.
Peroxide degradation condition
Accurately 5.0 ml aliquot of above stock solution was transferred into 
a 50 ml round bottom flask, and 3.0 ml of 3% H2O2 was added. The 
flask was kept at room temperature for 30 min then allowed to cool. 
Finally, volume was made up to the mark with MP, and the percentage 
of degradation was calculated.
RESULTS AND DISCUSSION
For selecting column chiral columns of OD52546 and SCDP52546, 
Inertsil was chosen to separate EMT, RIL, and TAF by injecting system 
suitability solution with the MP at 1.0 ml/min individually. Various 
solvents including water, ACN, triethyl amine, ammonium acetate, 
and methanol were used in different combinations to get good peaks 
resolutions and lesser runtime. Different flow rates from 0.4 to 
1 ml/min in gradient mode have been studied to achieve a good peak 
resolution. The column temperature was set at 25°, 30°, and 35°C for 
optimizing according to its effect on peak resolutions and RT of the drug 
samples. After performing several trails with various combinations 
of Methanol, ACN and buffer, an sharp and well resolved peaks were 
obtained using MP of 0.01 N phosphate buffer (pH:4):ACT in the ratio 
of 40:60 V/V. Under above-described experimental conditions, all the 
peaks were well defined and free from tailing.
System suitability
The RT of EMT, RIL, and TAF using optimum conditions was 2.517, 
3.273, and 6.697 min, respectively. The peak symmetries were <1.5, 
theoretical plates were >2000, and % relative standard deviation (RSD) 
was <2 as shown in Table 1.
Specificity
The specificity of the method was evaluated using placebo solution 
and a blank solution. Optimized chromatogram of EMT, RIL, and TAF is 
shown in Table 2 and Figs. 2-3.
Fig. 2: Optimized chromatogram of emtricitabine, rilpivirine, and 
tenofovir alafenamide
Fig. 3: Assay chromatogram of emtricitabine, rilpivirine, and 
tenofovir alafenamide
Table 1: System suitability results of EMT, RIL, and TAF
Parameter EMT RIL TAF
Peak area 1012865 1105605 1118501
Theoretical plates 2862.66 6433 6402.16
Retention time (min) 2.517 3.273 6.697
Tailing factor 0.96 1.22 1.335
EMT: Emtricitabine, RIL: Rilpivirine, TAF: Tenofovir alafenamide
Table 2: Results of assay of EMT, RIL, and TAF
Injection EMT RIL TAF
Average area 1079.485 1087.21 1744.953
Label claim (mg) 200 25 25
Amount found (mg) 200.08 24.93 25.60
Assay (%) 100.04 99.74 102.41
n=6; EMT: Emtricitabine, RIL: Rilpivirine, TAF: Tenofovir alafenamide
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Linearity
Weight accurately 13 mg of EMT, 1.62 mg of RIL, and 20 mg of TAF in 
100 ml of volumetric flask and dissolve in 10 ml of MP and make up 
the volume with MP. From the above stock solution, 13 µg/ml of EMT, 
1.62 µg/ml of RIL, and 20 µg/ml of TAF were prepared by diluting 
5.3 ml–10 ml with MP as shown in Table 3 and Figs. 4-6. The correlation 
coefficient for linear curve obtained between concentration and area 
for standard preparations of EMT, RIL, and TAF is 0.997, 0.993, and 
0.995.
System precision
The system precision of the proposed method was determined by 
analyzing the corresponding responses for three different days over 
a period of 1 week. One dilution of all the drugs in six replicates was 
injected into HPLC system and was analyzed as shown in the Table 4.
LOD and LOQ
LOD values for EMT, RIL, and TAF were 0.75, 0.253, and 0.253 μg/ml 
with signal-to-noise ratios of 3:1. LOQ values for EMT, RIL, and TAF 
were 2.254, 0.74, and 2.524 μg/ml with signal-to-noise ratios of 10:1.
Method precision
Precision was expressed as the closeness of agreement between a 
series of measurements obtaining from multiple sampling of the same 
homogeneous sample. Prepare sample preparations of EMT, RIL, and 
TAF as per test method and inject 6 times into the column as shown in 
Table 5.
Ruggedness
The ruggedness of the method was studied by the determining the 
analyst-to-analyst variation by performing the assay by two different 
analysts. The % RSD of assay values between two analysts should not 
be >2.0%. Results were found within the acceptance limits (RSD <2) as 
shown in Tables 6.
Accuracy
Accuracy of the method was determined by recovery studies. To the 
formulation (pre-analyzed sample), the reference standards of the 
drugs were added at the level of 50%, 100%, and 150%. The recovery 
studies were carried out 3 times and the percentage recovery and 
percentage mean recovery were calculated for drug as shown in 
Table 7. The percentage mean recovery of EMT, RIL, and TAF is 100%, 
101%, and 99%, respectively. The results are given in Table 7.
Robustness
To demonstrate the robustness of the method, prepare solution as 
per the test method and inject at different variable conditions using 
different conditions such as temperature and wavelength. System 
suitability parameters were compared with that of method precision. 
The result of the robustness study of the developed assay method is 
established in Table 8.
Forced stability studies
The stability studies were determined by applying the physical stress 
to the product. It was observed that there was marked degradation in 
the chromatograms. Results of forced degradation studies are shown 
in Table 9 and blank for control is recorded. Degradation studied was 
performed under different conditions, and in each condition, it was 
Table 3: Linearity data of EMT, RIL, and TAF.
EMT RIL TAF
Concentration (µg/ml) Peak area Concentration (µg/ml) Peak area Concentration (µg/ml) Peak area
24 631.586 3 659.236 30 1229.584
32 907.713 4 919.393 40 1482.509
40 1091.004 5 1086.050 50 1750.266
48 1339.312 6 1348.518 60 2124.626
56 1549.123 7 1552.332 70 2413.579
n=5; EMT: Emtricitabine, RIL: Rilpivirine, TAF: Tenofovir alafenamide
Fig. 4: Linearity graph of emtricitabine
Fig. 5: Linearity graph of rilpivirine
Fig. 6: Linearity graph of tenofovir alafenamide
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Table 4: System precision data of EMT, RIL, and TAF
S. No EMT RIL TAF
Retention time (min) Peak area Retention time (min) Peak area Retention time (min) Peak  area
Average 2.5190 1078.909 3.273 1088.830 6.700 1748.044
SD 0.002 14.836 0.003 14.708 0.008 22.745
% RSD 1.39 1.39 0.10 1.35 0.12 1.50
n=3; EMT: Emtricitabine, RIL: Rilpivirine, TAF: Tenofovir alafenamide. RSD: Relative standard deviation
Table 5: Method precision data of EMT, RIL, and TAF
S. No EMT RIL TAF
Retention time (min) Peak area Retention time (min) Peak area Retention time (min) Peak area
Average 2.5190 1078.909 3.273 1088.830 6.700 1748.044
SD 0.0024 14.836 0.003 14.708 0.008 22.745
% RSD 0.10 1.38 0.10 1.35 0.12 1.30
n=6; EMT: Emtricitabine, RIL: Rilpivirine, TAF: Tenofovir alafenamide, RSD: Relative standard deviation
Table 6: Ruggedness data of EMT, RIL, and TAF
Sample EMT RIL TAF
Analyst 1 100.86 100.479884 100.723731
Analyst 2 99.97565 100.51467 99.1048846
EMT: Emtricitabine, RIL: Rilpivirine, TAF: Tenofovir alafenamide
Table 7: Recovery data of EMT, RIL and TAF
Drug Sample (%) Amount (mg) Area % Mean % Average
EMT 50 32 930.06 102.87 100.19
100 40 1050.7 99.6
150 48 1300.2 98.1
RIL 50 4 930.02 102.52 101.3
100 5 1085.1 99.08
150 6 1380.5 102.5
TAF 50 40 930.02 99.21 99.7
100 50 1085.1 101.28
150 60 1380.5 98.13
n=3; EMT: Emtricitabine, RIL: Rilpivirine, TAF: Tenofovir alafenamide
Table 8: Robustness results of EMT, RIL, and TAF
Parameter EMT RIL TAF
Rt (min) Tf Rt (min) Tf Rt (min) Tf
Flow rate
1.0 ml/min 2.987 1.338 3.880 1.676 7.893 1.525
1.4 ml/min 2.167 1.758 2.810 1.354 5.700 1.550
Wavelength
260 nm 2.513 1.704 3.260 1.310 6.617 1.600
264 nm 2.490 1.769 3.240 1.310 6.627 1.565
Rt: Retention time, Tf: Tailing factor, EMT: Emtricitabine, RIL: Rilpivirine, 
TAF: Tenofovir alafenamide
observed that no interference of degradants with the analyte peak as 
shown in Figs. 7-11.
CONCLUSION
A simple, rapid, accurate, and precise stability-indicating HPLC analytical 
method had been developed and validated for the routine simultaneous 
estimation of EMT, RIL, and TAF in API and tablet dosage forms. The RT 
of EMT, RIL, and TAF using optimum conditions was 2.517, 3.273, and 
Fig. 7: Acid degradation of emtricitabine, rilpivirine, and 
tenofovir alafenamide
Fig. 8: Base degradation of emtricitabine, rilpivirine, and 
tenofovir alafenamide
Fig. 9: Thermal degradation of emtricitabine, rilpivirine, and 
tenofovir alafenamide
Fig. 10: Photolytic degradation of emtricitabine, rilpivirine, and 
tenofovir alafenamide
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Table 9: Stability studies results of EMT, RIL, and TAF
Condition EMT RIL TAF
Area % Degraded Area % Degraded Area % Degraded
Control 1078.909 - 1088.830 - 1748.044 -
Acid 988.107 6.25 1638.986 6.04 1229.216 6.70
Base 985.109 5.08 1649.683 5.19 1224.892 5.76
Peroxide 985.537 7.05 1641.595 6.99 1227.220 7.55
Thermal 985.109 3.42 1649.646 2.54 1224.892 3.59
Photo 985.023 1.85 1649.683 1.16 1224.559 2.32
EMT: Emtricitabine, RIL: Rilpivirine, TAF: Tenofovir alafenamide
6.697 min, respectively. The simplicity of the HPLC procedure, the short 
runtime, and the low volume of injection make this method suitable 
for quick and routine analysis. The stability indication nature of the 
analytical method provides confidence to use the developed method in 
a regulatory environment of the pharmaceutical industry without any 
further modification.
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